AMNEAL PHARMACEUTICALS, INC. (AMRX): what the price assumes

In the published model solve dated 2026-Q2, anchored at $17.44, AMNEAL PHARMACEUTICALS, INC. (AMRX) is priced for +6.3% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/AMRX

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 11: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.3% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is supported by earnings-power and relative-multiple value, while asset-based lands below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Earnings, Relative Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.9%); the inversion above states its own rate.

Per-Model Detail (n=7)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Three businesses share one roof here: a complex-generics arm that closed 2025 with 61 products with a pending ANDA and another 43 products in various stages of development in our pipeline, 95% of which are non-oral solid products, a small branded Specialty franchise built around the Parkinson's therapy CREXONT, and AvKARE, a government and institutional distributor supplying roughly a quarter of company revenue.
• Leverage governs everything else: net debt of $2.37 billion sits at 5.6 times trailing operating income of $424 million, and the share count has risen about 2.3% a year since early 2022 rather than falling.
• Second quarter results are scheduled for July 30, 2026, with the expanded iohexol contrast portfolio due to launch in the third quarter and Specialty's formulary momentum the thing to track behind it.

Bull Case

Mature is the stage label, and it should change what a reader counts as success. A mature drug business is not supposed to reinvent itself. It is supposed to replace revenue that decays with revenue that does not, faster than the decay arrives. Judged on that test, 2025 was a workmanlike year. Specialty revenue rose $82.8 million, and the company attributes the move to two named products: increases of $58.1 million and $23.7 million of CREXONT ® and UNITHROID ® , respectively. AvKARE added $81.8 million on top of that. Neither line is dramatic. Both are exactly the kind of increment that keeps a mature business from shrinking.

The durability argument sits in the generics arm, and it rests on manufacturing difficulty rather than scale. Amneal states the strategy plainly: it develops products that have substantial barriers-to-entry due to complex drug formulations or manufacturing. The pipeline reflects that choice, since the segment closed the year with 61 products with a pending ANDA and another 43 products in various stages of development in our pipeline, 95% of which are non-oral solid products. Injectables, transdermal patches, inhalation products and biosimilars are all harder to copy than a tablet. The practical consequence is fewer competitors per approval, and fewer competitors is what slows the price decay that defines commodity generics.

CREXONT is the cleanest example of a revenue stream that compounds rather than erodes. Insurance coverage, not prescribing enthusiasm, is the gate on a Parkinson's therapy, because a patient cannot fill what the plan will not pay for. The 10-K records that gate opening: CREXONT ® was added to three large national formularies, which expanded total U.S. insurance coverage from about 30% of covered lives at the end of 2024 to over 50% at the end of 2025. Roughly doubling the covered population inside a single year does not show up fully in that year's revenue. It shows up in the years after it.

Two more optional lines sit behind that. The FDA approved both biologics license applications for Boncresa ® , a biosimilar referencing Prolia ® , and Oziltus ® , a biosimilar referencing XGEVA ®, adding bone-health products to an oncology biosimilar book the company began commercializing in 2022, and recent respiratory approvals are meant to further strengthen our entry into complex inhaled and respiratory drug delivery. At a $5.9 billion market capitalization, neither needs to become large to matter.

What makes any of this bankable is that the operating business converts. Trailing revenue of $3.05 billion produced $424 million of operating income, a 14.5% operating margin. Set that beside the cohort: VTRS runs a 1.0% operating margin, PRGO is loss-making at the operating line, and TEVA is modestly ahead of Amneal. Free cash flow, the money left over once the plants and the equipment have been paid for, came to $240.8 million. Amneal is not the most profitable generics operator in its peer set, but it is nearer the top of that set than the bottom, and it is producing cash while carrying real debt. The bear is right that the leverage is heavy. The bull answer is that heavy leverage against a stable, cash-generating book is a very different proposition than heavy leverage against a shrinking one, and the 2025 revenue line grew.

Bear Case

Two future revenue streams are doing the heavy lifting in today's price, and they are not equally sturdy. The first is Specialty, where CREXONT's coverage expansion is real, observable and already disclosed. The second is the generics book simply holding its ground while Specialty compounds. The second assumption is the fragile one, and it covers the larger half of the company.

Start with what the price requires. At $17.93 the market is paying about 19 times company-wide operating income, which needs operating profit to compound at roughly 9.2% a year over about five years. The rate on its own is not exotic, and Amneal has delivered comparable growth recently. The persistence is the demand. Five consecutive years of high single-digit operating-profit growth from a business whose largest segment sells generics assumes that serious price erosion stays away for the whole window.

The filing does not describe that as a remote scenario. Amneal's own risk section says that when new entrants arrive, in some instances, price declines have exceeded 90%, and that competition has resulted in a significant decline in our revenue and gross margin from time to time. Concentration sharpens the point: our significant product families (defined as our top five products by annual revenue including both our Affordable Medicines and Specialty segments) accounted for 25% of our consolidated net revenue. A quarter of the revenue base sits in five products, and each of those is one competitor away from a materially different price.

Leverage is what turns a revenue disappointment into an equity problem. Trailing operating income is $424 million against an enterprise valued near $8.1 billion, so shareholders stand behind lenders on a business where borrowed money is the larger claim. Net debt of $2.37 billion is 5.6 times operating income. Take a tenth off the operating line and the borrowings do not move; the equity absorbs the whole adjustment. The share count has been drifting the wrong way as well, up about 2.3% a year since early 2022, so per-share progress requires the operating line to outrun the count before it does anything for a holder.

None of the standard ways of valuing this company reaches the current price. The peer-multiple methods land roughly a third below it and the earnings-power methods roughly half below, so the premium is not defended by any conventional frame. It is defended by the expectation of five more good years in a row. The bull answer is that complex formulations erode more slowly than commodity tablets, which is true and is exactly why almost the whole pipeline sits outside oral solids. The bear answer is that the language about post-entry price collapse was written by this company about its own markets, and complex products arrive at the same place once the second and third filers show up.

Valuation

Start with what $17.93 has to assume. The price works out to about 19 times company-wide operating income, and running that multiple backwards gives an operating-profit growth requirement of roughly 9.2% a year over about five years. Read the two halves separately, because they carry different weight. The rate sits inside what Amneal has recently delivered. The persistence is the part being paid for.

Every family of method used to triangulate the business lands below the quoted price, which is unusual enough to state plainly. The peer-multiple lens, which prices Amneal off what the market pays for comparable earnings and EBITDA streams, sits roughly a third under today's price. The lens built on current earning power sits roughly half under. Nothing in that pattern says the price is wrong. It says the price is not supported by any of the static frames, so the support has to come entirely from the forward story.

The reported inputs underneath those readings are unremarkable and reasonably clean. Trailing revenue of $3.05 billion produced operating income of $424 million, a 14.5% operating margin. The 2025 revenue growth came from identifiable places rather than mix noise, with Specialty up $82.8 million on increases of $58.1 million and $23.7 million of CREXONT ® and UNITHROID ® , respectively and AvKARE up $81.8 million. Free cash flow, the money left over once the plants and the equipment have been paid for, came to $240.8 million.

Cohort position is where the premium becomes legible. VTRS runs a 1.0% operating margin and PRGO is loss-making at the operating line, while TEVA, the largest peer in the set, sits ahead of Amneal at a 16.2% operating margin. The generics peer group is, on the whole, either shrinking or barely profitable, which is exactly why a mid-teens operating result paired with a growing branded book gets paid a premium multiple at all. It also means the comparison set supplies very little cushion: if Amneal's own decay curve steepens, the peers are not a floor, because most of them already sit below the level Amneal is being credited for.

The balance sheet decides how much of that premium is survivable. Net debt of $2.37 billion works out to 5.6 times operating income, which is real leverage for a company whose largest segment sells into a market where competition erodes value fast. Liquid assets total $198 million, so a bad year gets absorbed by the revolver rather than by the cushion. The maturity question, at least, has been pushed out, since On February 2, 2026, the Company entered into a repricing amendment to the Term Loan Credit Agreement governing the Term Loan Due 2032 lowered the spread again on borrowings that now run to 2032. What refinancing does not change is the arithmetic underneath it, where the operating line has to keep compounding for the equity to compound, and a share count rising about 2.3% a year means it has to compound slightly faster than the headline suggests.

Catalysts

The near-term calendar is dense. Amneal reports second quarter 2026 results on July 30, 2026. The first quarter print in May set the bar: net revenue of $723 million, up 4% against the prior-year quarter, with Specialty revenue up 23%. Management reaffirmed its full-year 2026 net revenue guidance range of $3.05 billion to $3.15 billion at that print.

Two regulatory events in July give the second half its shape. On July 17, 2026 the FDA approved additional strengths and vial presentations of Amneal's iohexol injection, the imaging contrast agent, with commercial launch planned for the third quarter. Iohexol is the kind of product the complex-injectables strategy exists to serve: difficult to manufacture, sold into hospital systems, and not something a competitor replicates in a quarter.

The larger option was accepted for review nine days earlier. On July 8, 2026 the FDA accepted two abbreviated applications for a generic tirzepatide autoinjector developed with Adalvo, with Amneal leading commercialization. Acceptance is not approval, and the path for a first generic of a blockbuster metabolic drug delivered by autoinjector is measured in years and litigation rather than quarters. The capability, at least, is not hypothetical: auto-injector products already account for roughly 8% of company revenue, so the manufacturing question is settled even though the legal and regulatory ones are not.

Peer Cohorts (Per Segment, With Filing Citations)

F-67 (reported)

• TEVA (TEVA PHARMACEUTICAL INDUSTRIES LIMITED)
• FY2025 10-K: …in violation of such laws, whether carried out in the United States or elsewhere in connection with the conduct of our business have exposed us, and may further expose us, to significant liability for violations of the FCPA or other anti-corruption laws. In 2016, we paid a monetary fine for FCPA violations and…
• FY2025 10-K: …of the product in the U.S. On January 13, 2025, we announced we entered into a collaboration agreement with Formycon for the commercialization of FYB203, Formycon's biosimilar candidate to Eylea ® (aflibercept) in Europe (excluding Italy), the United Kingdom, Switzerland and in Israel, for the treatment of…
• VTRS (Viatris Inc)
• FY2025 10-K: …extension study for EFFEXOR® required for approval in Japan. The Company also filed applications to the Japan Ministry of Health, Labor and Welfare for approval of EFFEXOR SR Capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor to treat adults with generalized anxiety disorder, an…
• FY2025 10-K: Information Statement included as Exhibit 99.1 to the Report on Form 8-K filed by Upjohn Inc. with the SEC on August 6, 2020, and incorporated herein by reference . ^ 2.2(a) Separation and Distribution Agreement, dated as of July 29, 2019, by and between Pfizer Inc. and Upjohn Inc., filed as Exhibit 2.2 to the Report…
• OGN (Organon & Co.)
• FY2025 10-K: …things, (i) extended the maturity of the U.S. Dollar Term Loan Facility to May 17, 2031, (ii) extended the maturity of the revolving credit loans made under the Revolving Credit Facility to December 2, 2027, (iii) increased the maximum amount of the Revolving Credit Facility by $ 300 million and decreased the…
• FY2025 10-K: …prostate and Propecia ® (finasteride), used for the treatment of male pattern hair loss. Research and Development As part of our growth strategy, we will opportunistically identify scientific collaborations and acquisitions to complement our women's health portfolio and/or expand our general medicines portfolio with…
• BHC (Bausch Health Companies Inc.)
• FY2025 10-K: …our products as the result of the concentration of sales to wholesalers; • the effect of fluctuations in inventory levels or buying patterns by our large distributor and retail customers; • the decline in pricing and/or volume of our products under our distribution agreements with other companies; • risks associated…
• FY2025 10-K: …bhc:BauschLombMember us-gaap:SecuredDebtMember 2024-12-31 0000885590 bhc:IncrementalTermLoanBDueMay2027Member bhc:BauschLombMember us-gaap:SecuredDebtMember 2025-12-31 0000885590 bhc:IncrementalTermLoanBDueMay2027Member bhc:BauschLombMember us-gaap:SecuredDebtMember 2024-12-31 0000885590…
• PRGO (Perrigo Company plc)
• FY2025 10-K: …to the end of the period for which net sales are being measured. Notable new product launches in the year ended December 31, 2025 include Phenylephrine No Drip Nasal Spray, IBU/APAP Dual Active and the Trios TM program launch in CSCA and CSCI line extensions in the Bronchostop ® 5 in1 products, flavor roll outs in…
• FY2025 10-K: …D. Ashford Chairman of the Board Orlando D. Ashford /s/ Bradley A. Alford Director Bradley A. Alford /s/ Julia Brown Director Julia Brown /s/ Kevin Egan Director Kevin Egan /s/ Adriana Karaboutis Director Adriana Karaboutis /s/ Jeffrey B. Kindler Director Jeffrey B. Kindler /s/ Albert A. Manzone Director Albert A.…
• INDV (Indivior Pharmaceuticals, Inc.)
• FY2025 10-K: …0001625297 2025 FY FALSE one one .6667 http://fasb.org/us-gaap/2025#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2025#ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure indv:productLine indv:segment indv:plan indv:claim indv:state…
• FY2025 10-K: …ceased all detailing of the product in that year, though it remains available for sale. Launch of SUBLOCADE in the U.S. The FDA approved SUBLOCADE (buprenorphine extended-release injection for subcutaneous use ) in November 2017 and we launched sales of this product in 2018. As the first monthly buprenorphine-based…
• CPRX (CATALYST PHARMACEUTICALS, INC.)
• FY2025 10-K: …that affects more than 50 million individuals globally, 80% of whom live in developing countries. An estimated 1.7% of U.S. adults have been diagnosed with the condition. From prominent historical figures to friends or family members, most people probably know someone affected by epilepsy. The FDA approved FYCOMPA®…
• FY2025 10-K: …agreement with KYE for this product, we will supply product to KYE and also receive sales milestones and sales royalties based on net revenues from sales of the product in Canada. FYCOMPA® On December 17, 2022, we entered into an agreement with Eisai Co., Ltd. (Eisai) for the acquisition of the U.S. rights to…
• PBH (PRESTIGE CONSUMER HEALTHCARE INC.)
• FY2025 10-K: …0001295947 2025 FY FALSE Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure pbh:segment…
• FY2025 10-K: …The 67 RSUs provide for accelerated vesting if there is a change of control, as defined in the 2005 Plan and the 2020 Plan. The RSUs granted to employees generally vest either ratably over three years or in their entirety on the three-year anniversary of the date of the grant. Upon vesting, the units will be settled…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.